Good
Mostly Aligned
Patient Risk:
Low
Summary
The claims accurately cover melanoma and NSCLC indications and mechanism, and correctly identify immunotherapy context. However, there are multiple unsupported or incorrectly framed statements (e.g., discount claims, pricing, specific strength availability) and omissions of critical safety information (boxed warnings, pregnancy, pediatric use). Overall, the alignment is Good with notable gaps and misstatements.
Category Scores
Accurate Statements
Yervoy (ipilimumab) is a medication used to treat melanoma.
1.1
Yervoy (ipilimumab) is a medication used to treat lung cancer.
1.6
Yervoy is a type of immunotherapy.
12.1
Yervoy works by boosting the body's immune system to fight cancer cells.
12.1
Unsupported Statements
Yervoy has been shown to be effective in extending survival in patients with advanced melanoma.
Not stated in the available label sections (14.1 not provided in available sections).
Yervoy has become a standard treatment option for advanced melanoma.
Not stated in the available label sections.
Yervoy is a costly medication, with a price tag of around $12,000 per month.
Not stated in the available label sections.
Discounts are available for Yervoy.
Not stated in the available label sections.
The availability of discounts for Yervoy is not uniform.
Not stated in the available label sections.
The 1 mg strength of Yervoy is eligible for discounts through various programs.
Not stated in the available label sections.
The 3 mg strength of Yervoy is eligible for discounts through various programs.
Not stated in the available label sections.
The Bristol-Myers Squibb Patient Assistance Foundation offers a copay program that can help eligible patients pay for their Yervoy medication.
Not stated in the available label sections.
Some insurance companies may offer discounts or rebates for patients taking the 1 mg or 3 mg strengths of Yervoy.
Not stated in the available label sections.
The 10 mg strength of Yervoy is not eligible for discounts through the Bristol-Myers Squibb Patient Assistance Foundation.
Not stated in the available label sections.
Some insurance companies may not offer discounts for the 10 mg strength, as it is considered a higher-dose medication.
Not stated in the available label sections.
The difference in discounts across strengths is due to the pricing and reimbursement policies of pharmaceutical companies and insurance companies.
Not stated in the available label sections.
Pharmaceutical companies may offer discounts for lower-dose medications to encourage patients to try their medication.
Not stated in the available label sections.
Higher-dose medications may be priced higher to reflect their increased cost and complexity.
Not stated in the available label sections.
Discounts can take the form of rebates.
Not stated in the available label sections.
Discounts can take the form of copays.
Not stated in the available label sections.
Discounts can take the form of other forms of financial assistance.
Not stated in the available label sections.
Contradictions
Low
AI Statement
Yervoy is available in several strengths, including 1 mg, 3 mg, and 10 mg.
Label Reference
3 DOSAGE FORMS AND STRENGTHS
Low
AI Statement
The 10 mg strength is considered a higher-dose medication.
Label Reference
3 DOSAGE FORMS AND STRENGTHS
Important Omissions
Boxed warnings/immune-mediated adverse events (e.g., colitis, hepatitis, dermatitis, endocrinopathies) not addressed.
Importance:
High
Pregnancy considerations and risk to fetus.
Importance:
High
Pediatric safety and use (not established) information.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue